GVS announced that it has entered into a binding agreement with Ningbo Fuji Medical Technology Co., Ltd., a company controlled by Shanghai Fosun Pharmaceutical (Group) Co., Ltd., to acquire the entire share capital of Shanghai Transfusion Technology Co., Ltd., a Shanghai headquartered company active in the production and sale of blood management related products.
The acquisition of the Company represents a unique strategic opportunity for GVS to fully enter into the healthcare Chinese market with expected synergies in the commercial, industrial and branding area.
Massimo Scagliarini, CEO of GVS, commented: “The acquisition of this historic brand STT, a leader in China’s blood management sector, puts us in a privileged position to expand our Group’s presence in the Chinese market. This acquisition, together with the recent opening of three distribution centers in Malaysia, Thailand and Vietnam, will allow us to consolidate our positioning in the Chinese and Asian healthcare segment by promoting our entire product line”.
For further information on the operation, it is possible to download the press release at the below link:
